J.M. Van der Velden
Utrecht University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J.M. Van der Velden.
Radiotherapy and Oncology | 2017
A.S. Gerlich; J.M. Van der Velden; Alexis N.T.J. Kotte; Chia-Lin Tseng; G. Fanetti; W.S.C. Eppinga; N. Kasperts; M. Intven; Frank A. Pameijer; M.E.P. Philippens; Helena M. Verkooijen; E. Seravalli
BACKGROUND AND PURPOSE The use of Stereotactic Body Radiotherapy (SBRT) for bone metastases is increasing rapidly. Therefore, knowledge of the inter-observer differences in tumor volume delineation is essential to guarantee precise dose delivery. The aim of this study is to compare inter-observer agreement in bone metastases delineated on different imaging modalities. MATERIAL AND METHODS Twenty consecutive patients with bone metastases treated with SBRT were selected. All patients received CT and MR imaging in treatment position prior to SBRT. Five observers from three institutions independently delineated gross tumor volume (GTV) on CT alone, CT with co-registered MRI and MRI alone. Four contours per imaging modality per patient were available, as one set of contours was shared by 2 observers. Inter-observer agreement, expressed in generalized conformity index [CIgen], volumes of contours and contours center of mass (COM) were calculated per patient and imaging modality. RESULTS Mean GTV delineated on MR (45.9±52.0cm3) was significantly larger compared to CT-MR (40.2±49.4cm3) and CT (34.8±41.8cm3). A considerable variation in CIgen was found on CT (mean 0.46, range 0.15-0.75) and CT-MRI (mean 0.54, range 0.17-0.71). The highest agreement was found on MRI (mean 0.56, range 0.20-0.77). The largest variations of COM were found in anterior-posterior direction for all imaging modalities. CONCLUSIONS Large inter-observer variation in GTV delineation exists for CT, CT-MRI and MRI. MRI-based GTV delineation resulted in larger volumes and highest consistency between observers.
Medical Physics | 2014
Stan J. Hoogcarspel; C Kontaxis; J.M. Van der Velden; G.H. Bol; M. van Vulpen; J.J.W. Lagendijk; B W Raaymakers
PURPOSE To develop an MR accelerator-enabled online planning-todelivery technique for stereotactic palliative radiotherapy treatment of spinal metastases. The technical challenges include; automated stereotactic treatment planning, online MR-based dose calculation and MR guidance during treatment. METHODS Using the CT data of 20 patients previously treated at our institution, a class solution for automated treatment planning for spinal bone metastases was created. For accurate dose simulation right before treatment, we fused geometrically correct online MR data with pretreatment CT data of the target volume (TV). For target tracking during treatment, a dynamic T2-weighted TSE MR sequence was developed. An in house developed GPU based IMRT optimization and dose calculation algorithm was used for fast treatment planning and simulation. An automatically generated treatment plan developed with this treatment planning system was irradiated on a clinical 6 MV linear accelerator and evaluated using a Delta4 dosimeter. RESULTS The automated treatment planning method yielded clinically viable plans for all patients. The MR-CT fusion based dose calculation accuracy was within 2% as compared to calculations performed with original CT data. The dynamic T2-weighted TSE MR Sequence was able to provide an update of the anatomical location of the TV every 10 seconds. Dose calculation and optimization of the automatically generated treatment plans using only one GPU took on average 8 minutes. The Delta4 measurement of the irradiated plan agreed with the dose calculation with a 3%/3mm gamma pass rate of 86.4%. CONCLUSIONS The development of an MR accelerator-enabled planning-todelivery technique for stereotactic palliative radiotherapy treatment of spinal metastases was presented. Future work will involve developing an intrafraction motion adaptation strategy, MR-only dose calculation, radiotherapy quality-assurance in a magnetic field, and streamlining the entire treatment process on an MR accelerator.
Pharmacy World & Science | 1994
C. C. M. Veninga; P. Denig; F. M. Haaijer-Ruskamp; F. W. Dijkers; B. Meyboom-de Jong; Corinne S. de Vries; Jos W. Timmer; Lolkje de Jong van den Berg; M.E.C. van Eijk; A. de Boer; Th. J. E. van Hemert; Johan A. van der Horn; Antonius G. M. Steerneman; Lolkje de Jong-van den Berg; M. E. c. de Wit; B.H.Ch. Stricker; A. J. Porsius; E. Th. J. Peters; G. Th. van der Werf; R. Hoek; J. P. Ottervanger; J.M. Van der Velden; A. C. G. Egberts; R. H. B. Mayboom; G. H. P. de Koning; M. C. van Ermen; T. Roisin; X. Kurz; Floor Rikken; Rein Vos
Family Practice | 1995
R A de Melker; J.M. Van der Velden; Marijke M. Kuyvenhoven
Radiotherapy and Oncology | 2017
A.S. Gerlich; J.M. Van der Velden; G. Fanetti; A. Zoetelief; W.S.C. Eppinga; E. Seravalli
Radiotherapy and Oncology | 2018
B. Pielkenrood; L. Pogoda; J.M. Van der Velden; Helena M. Verkooijen; Jorrit-Jan Verlaan; N. Kasperts
Radiotherapy and Oncology | 2017
A.S. Gerlich; J.M. Van der Velden; Alexis N.T.J. Kotte; Chia-Lin Tseng; G. Fanetti; W.S.C. Eppinga; N. Kasperts; M. Intven; Frank A. Pameijer; M.E.P. Philippens; Helena M. Verkooijen; E. Seravalli
Radiotherapy and Oncology | 2017
A.S. Gerlich; J.M. Van der Velden; Alexis N.T.J. Kotte; Chia-Lin Tseng; G. Fanetti; W.S.C. Eppinga; N. Kasperts; M. Intven; Frank A. Pameijer; M.E.P. Philippens; Helena M. Verkooijen; E. Seravalli
Radiotherapy and Oncology | 2017
F Prins; J.M. Van der Velden; A.S. Gerlich; Alexis N.T.J. Kotte; W.S.C. Eppinga; N. Kasperts; Linda G W Kerkmeijer
Radiotherapy and Oncology | 2017
G. Fanetti; A.S. Gerlich; E. Seravalli; Helena M. Verkooijen; M. van Vulpen; R. Orecchia; B.A. Jereczek-Fossa; J.M. Van der Velden